Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 3.8%

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shot up 3.8% during trading on Tuesday . The company traded as high as $14.44 and last traded at $14.38. 233,012 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 608,511 shares. The stock had previously closed at $13.85.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DAWN. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $40.60.

Day One Biopharmaceuticals Stock Performance

The company has a fifty day moving average price of $15.23 and a two-hundred day moving average price of $13.67.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the completion of the transaction, the insider now directly owns 1,184,662 shares in the company, valued at $18,966,438.62. The disclosure for this sale can be found here. Insiders have sold a total of 45,781 shares of company stock valued at $722,960 over the last ninety days. 8.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its holdings in Day One Biopharmaceuticals by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after buying an additional 1,445 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Day One Biopharmaceuticals by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 4,769,746 shares of the company’s stock worth $69,638,000 after acquiring an additional 139,992 shares during the period. Fisher Asset Management LLC increased its holdings in Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock worth $999,000 after acquiring an additional 32,238 shares during the last quarter. Wellington Management Group LLP increased its holdings in Day One Biopharmaceuticals by 77.7% in the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock worth $3,051,000 after acquiring an additional 91,393 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after acquiring an additional 472,654 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.